

# Erik S G Stroes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2181865/publications.pdf>

Version: 2024-02-01

175  
papers

23,528  
citations

19608

61  
h-index

7931

149  
g-index

180  
all docs

180  
docs citations

180  
times ranked

20842  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2022, 43, 830-833.	1.0	92
2	Finding very high lipoprotein(a): the need for routine assessment. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 769-776.	0.8	29
3	Working towards full eradication of lipid-driven cardiovascular risk?. <i>Netherlands Heart Journal</i> , 2022, 30, 15-24.	0.3	2
4	The challenge of choosing in cardiovascular risk management. <i>Netherlands Heart Journal</i> , 2022, 30, 47-57.	0.3	5
5	Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. <i>Heart</i> , 2022, 108, 61-66.	1.2	18
6	Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia. <i>Atherosclerosis</i> , 2022, 340, 61-67.	0.4	6
7	Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. <i>Atherosclerosis</i> , 2022, 341, 43-49.	0.4	28
8	Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et al. <i>Heart</i> , 2022, 108, 576-577.	1.2	0
9	Targeted proteomics improves cardiovascular risk prediction in secondary prevention. <i>European Heart Journal</i> , 2022, 43, 1569-1577.	1.0	55
10	Lipoprotein(a) Induces Vesicular Cardiovascular Calcification Revealed With Single-Extracellular Vesicle Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 778919.	1.1	12
11	Reduced baroreflex sensitivity and increased splenic activity in patients with severe obstructive sleep apnea. <i>Atherosclerosis</i> , 2022, 344, 7-12.	0.4	1
12	Lipoprotein(a): An underestimated inflammatory mastermind. <i>Atherosclerosis</i> , 2022, 349, 101-109.	0.4	32
13	Considerations for routinely testing for high Lp(a). <i>Current Opinion in Lipidology</i> , 2022, 33, 213-218.	1.2	4
14	Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study. <i>BMJ Open</i> , 2021, 11, e045482.	0.8	35
15	Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease. <i>Scientific Reports</i> , 2021, 11, 4126.	1.6	2
16	From evidence to practice: development of web-based Dutch lipid reference values. <i>Netherlands Heart Journal</i> , 2021, 29, 441-450.	0.3	6
17	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275.	5.5	109
18	Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2038-2048.	1.1	48

#	ARTICLE	IF	CITATIONS
19	Marked plaque regression in homozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 327, 13-17.	0.4	35
20	Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic <i>&lt;i&gt;LPA&lt;/i&gt;</i> Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003271.	1.6	11
21	Lipoprotein(a) Measurement in Clinical Practice. <i>JAMA Internal Medicine</i> , 2021, 181, 1138.	2.6	0
22	Impact of cholesterol on proinflammatory monocyte production by the bone marrow. <i>European Heart Journal</i> , 2021, 42, 4309-4320.	1.0	31
23	PCSK9 Inhibition and Oxidized Phospholipids. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1288-1289.	1.2	6
24	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	1.0	303
25	Next-generation sequencing to confirm clinical familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 875-883.	0.8	23
26	Sympathetic activation by lower body negative pressure decreases kidney perfusion without inducing hypoxia in healthy humans. <i>Clinical Autonomic Research</i> , 2020, 30, 149-156.	1.4	4
27	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of <sup>89</sup> Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. <i>Bioconjugate Chemistry</i> , 2020, 31, 360-368.	1.8	22
28	Dynamic magnetic resonance measurements of calf muscle oxygenation and energy metabolism in peripheral artery disease. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 98-107.	1.9	13
29	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 593-603.	0.8	224
30	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
31	Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2020, 63, 597-610.	2.9	60
32	The therapeutic age paradox coming to an end. <i>European Heart Journal</i> , 2020, 41, 2259-2261.	1.0	2
33	Netrin-1 and the Grade of Atherosclerosis Are Inversely Correlated in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 462-472.	1.1	17
34	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. <i>Atherosclerosis</i> , 2020, 311, 13-19.	0.4	21
35	Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects. <i>Atherosclerosis</i> , 2020, 306, 15-21.	0.4	9
36	Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 581641.	1.8	29

#	ARTICLE	IF	CITATIONS
37	BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes. <i>Clinical Epigenetics</i> , 2020, 12, 166.	1.8	25
38	Next-generation sequencing to confirm clinical familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2020, , 204748732094299.	0.8	12
39	Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease. <i>Circulation</i> , 2020, 142, 1996-1998.	1.6	81
40	Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema. <i>New England Journal of Medicine</i> , 2020, 383, 1242-1247.	13.9	28
41	Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy. <i>Stroke</i> , 2020, 51, 2972-2982.	1.0	16
42	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. <i>European Heart Journal</i> , 2020, 41, 3998-4007.	1.0	68
43	Gene-based therapy in lipid management: the winding road from promise to practice. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 483-493.	1.9	20
44	Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a). <i>Lipids in Health and Disease</i> , 2020, 19, 91.	1.2	4
45	A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. <i>Cardiology and Therapy</i> , 2020, 9, 447-465.	1.1	6
46	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232
47	Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 355-361.	0.6	25
48	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. <i>Circulation Research</i> , 2020, 126, 1346-1359.	2.0	96
49	The dedicated "Lp(a) clinic": A concept whose time has arrived?. <i>Atherosclerosis</i> , 2020, 300, 1-9.	0.4	52
50	Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Disease-Free Survival, and Mortality Risk. <i>JAMA Network Open</i> , 2020, 3, e200129.	2.8	27
51	Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). <i>European Heart Journal</i> , 2020, 41, 2262-2271.	1.0	65
52	Surmounting the endothelial barrier for delivery of drugs and imaging tracers. <i>Atherosclerosis</i> , 2020, 315, 93-101.	0.4	4
53	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2019, 381, 531-542.	13.9	359
54	Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1780.	3.8	314

#	ARTICLE	IF	CITATIONS
55	PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2571-2573.	2.3	44
56	Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia. <i>Cell Metabolism</i> , 2019, 30, 1-2.	7.2	130
57	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2150-2162.	1.2	187
58	Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. <i>Journal of the American Heart Association</i> , 2019, 8, e011662.	1.6	292
59	Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases. <i>Marine Drugs</i> , 2019, 17, 699.	2.2	22
60	Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease. <i>EBioMedicine</i> , 2019, 39, 109-117.	2.7	42
61	Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. <i>European Heart Journal</i> , 2019, 40, 2775-2781.	1.0	95
62	FISHing for the Miracle of Eicosapentaenoic Acid. <i>New England Journal of Medicine</i> , 2019, 380, 89-90.	13.9	66
63	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , 2019, 139, 1483-1492.	1.6	533
64	Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. <i>Nature Biomedical Engineering</i> , 2018, 2, 279-292.	11.6	94
65	Inflammation-Sensitive Myosin-X Functionally Supports Leukocyte Extravasation by Cdc42-Mediated ICAM-1-Rich Endothelial Filopodia Formation. <i>Journal of Immunology</i> , 2018, 200, 1790-1801.	0.4	28
66	PCSK9 inhibitors in clinical practice: Delivering on the promise?. <i>Atherosclerosis</i> , 2018, 270, 205-210.	0.4	45
67	CCR2 expression on circulating monocytes is associated with arterial wall inflammation assessed by 18F-FDG PET/CT in patients at risk for cardiovascular disease. <i>Cardiovascular Research</i> , 2018, 114, 468-475.	1.8	43
68	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 119-127.	1.4	17
69	Prolonged hematopoietic and myeloid cellular response in patients after an acute coronary syndrome measured with 18F-DPA-714 PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1956-1963.	3.3	7
70	Effect of Vegan Fecal Microbiota Transplantation on Carnitine- and Choline-Derived Trimethylamine-N-Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	164
71	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. <i>European Heart Journal</i> , 2018, 39, 3521-3527.	1.0	44
72	Characterization of immune cell, endothelial, and renal responses upon experimental human endotoxemia. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018, 89, 39-46.	0.3	16

#	ARTICLE	IF	CITATIONS
73	Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. <i>Data in Brief</i> , 2018, 21, 1334-1336.	0.5	4
74	From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. <i>Cardiovascular Research</i> , 2018, 114, 1714-1727.	1.8	63
75	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 948-955.	0.8	46
76	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. <i>European Heart Journal</i> , 2018, 39, 2589-2596.	1.0	100
77	Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 365-372.	1.3	19
78	Consistent LDL- $\Delta$ C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , 2018, 41, 1328-1335.	0.7	25
79	Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". <i>Atherosclerosis</i> , 2018, 275, 265-272.	0.4	131
80	Diagnostic algorithm for familial chylomicronemia syndrome. <i>Atherosclerosis Supplements</i> , 2017, 23, 1-7.	1.2	94
81	How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population. <i>Diabetologia</i> , 2017, 60, 1271-1275.	2.9	20
82	How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. <i>Atherosclerosis Supplements</i> , 2017, 26, 16-24.	1.2	24
83	Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 969-975.	1.1	85
84	Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	61
85	Nile Red Quantifier: a novel and quantitative tool to study lipid accumulation in patient-derived circulating monocytes using confocal microscopy. <i>Journal of Lipid Research</i> , 2017, 58, 2210-2219.	2.0	20
86	The maturation of a "neural"hematopoietic" inflammatory axis in cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2017, 28, 507-512.	1.2	8
87	Arterial and Cellular Inflammation in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1278-1285.	3.0	46
88	PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2017, 38, 1584-1593.	1.0	141
89	Intestinal <i>Ralstonia pickettii</i> augments glucose intolerance in obesity. <i>PLoS ONE</i> , 2017, 12, e0181693.	1.1	53
90	Impact of the B Cell Growth Factor APRIL on the Qualitative and Immunological Characteristics of Atherosclerotic Plaques. <i>PLoS ONE</i> , 2016, 11, e0164690.	1.1	9

#	ARTICLE	IF	CITATIONS
91	Increased haematopoietic activity in patients with atherosclerosis. <i>European Heart Journal</i> , 2016, 38, ehw246.	1.0	62
92	Oral treatment with <i>Eubacterium hallii</i> improves insulin sensitivity in db/db mice. <i>Npj Biofilms and Microbiomes</i> , 2016, 2, 16009.	2.9	159
93	Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 297-304.	1.3	23
94	Magnetic Resonance Imagingâ€‘Derived Renal Oxygenation and Perfusion During Continuous, Steadyâ€‘State Angiotensinâ€‘II Infusion in Healthy Humans. <i>Journal of the American Heart Association</i> , 2016, 5, e003185.	1.6	23
95	Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1463-1470.	1.7	32
96	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. <i>Circulation</i> , 2016, 134, 611-624.	1.6	396
97	Carotid arterial wall inflammation in peripheral artery disease is augmented by type 2 diabetes: a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 237.	0.7	7
98	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160Âmg/dl or Higher. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 473-483.	1.3	160
99	Thresholds for Arterial Wall Inflammation Quantified by 18F-FDG PET Imaging. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1198-1207.	2.3	81
100	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	71
101	Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1848-1851.	0.5	26
102	Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2016, 18, 115.	1.6	30
103	HDL infusion for the management of atherosclerosis. <i>Current Opinion in Lipidology</i> , 2016, 27, 592-596.	1.2	12
104	InÂVivo PET Imaging of HDL in MultipleÂAtherosclerosisÂModels. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 950-961.	2.3	78
105	Câ€‘Reactive Protein Identifies Lowâ€‘Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancerâ€‘Norfolk Prospective Population Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	23
106	Current therapies for lowering lipoprotein (a). <i>Journal of Lipid Research</i> , 2016, 57, 1612-1618.	2.0	77
107	Comparison of <sc>PCSK9</sc> Inhibitor Evolocumab vs Ezetimibe in Statinâ€‘Intolerant Patients: Design of the Goal Achievement After Utilizing an Antiâ€‘<sc>PCSK9</sc> Antibody in Statinâ€‘Intolerant Subjects 3 (<sc>GAUSS</sc>â€‘3) Trial. <i>Clinical Cardiology</i> , 2016, 39, 137-144.	0.7	32
108	Increasing the Spatial Resolution of 3T Carotid MRI Has No Beneficial Effect for Plaque Component Measurement Reproducibility. <i>PLoS ONE</i> , 2015, 10, e0130878.	1.1	8

#	ARTICLE	IF	CITATIONS
109	Statin-associated muscle symptoms: impact on statin therapyâ€”European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	1.0	1,024
110	Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1133-1140.	1.7	37
111	Guideline treatment results in regression of atherosclerosis in type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 126-132.	0.9	4
112	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. <i>Science Advances</i> , 2015, 1, .	4.7	173
113	Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon-Injury Model. <i>PLoS ONE</i> , 2015, 10, e0122836.	1.1	6
114	The Effect of a Diiodothyronine Mimetic on Insulin Sensitivity in Male Cardiometabolic Patients: A Double-Blind Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e86890.	1.1	30
115	Adrenal Function in Females with Low Plasma HDL-C Due to Mutations in ABCA1 and LCAT. <i>PLoS ONE</i> , 2014, 9, e90967.	1.1	12
116	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157.	1.0	835
117	Effects of an Antisense Oligonucleotide Inhibitor of C-reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	33
118	HDL does not influence the polarization of human monocytes toward an alternative phenotype. <i>International Journal of Cardiology</i> , 2014, 172, 179-184.	0.8	23
119	Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2541-2548.	1.2	465
120	Design and Rationale of the <sc>GAUSS</sc>-2 Study Trial: A Double-blind, Ezetimibe-controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (<sc>AMG</sc> 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy. <i>Clinical Cardiology</i> , 2014, 37, 131-139.	0.7	25
121	Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1418-1426.	1.2	90
122	A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. <i>Nature Communications</i> , 2014, 5, 3065.	5.8	336
123	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 655-666.	5.5	473
124	Carriers of Loss-of-Function Mutations in EXT Display Impaired Pancreatic Beta-Cell Reserve Due to Smaller Pancreas Volume. <i>PLoS ONE</i> , 2014, 9, e115662.	1.1	12
125	Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies. <i>Clinical Lipidology</i> , 2013, 8, 321-328.	0.4	0
126	Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490.	1.0	2,132

#	ARTICLE	IF	CITATIONS
127	ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. <i>European Heart Journal</i> , 2013, 34, 286-291.	1.0	61
128	High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C. <i>Journal of Lipid Research</i> , 2013, 54, 1698-1704.	2.0	45
129	The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 3143-3149.	0.9	24
130	Novel anti-inflammatory strategies in atherosclerosis. <i>Current Opinion in Lipidology</i> , 2012, 23, 532-539.	1.2	39
131	PS3 - 15. Genetic Variation at the SULF2 Locus Affects Hepatic Postprandial Remnant Clearance in Patients with Type 2 Diabetes Mellitus. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012, 10, 109-109.	0.0	0
132	PS14 - 68. Differential effects of antibiotics on bile acid metabolism, intestinal microbiota composition and insulin resistance in obese humans; a randomised controlled trial. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012, 10, 147-147.	0.0	0
133	Lipid Oxidation in Carriers of Lecithin:Cholesterol Acyltransferase Gene Mutations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 3066-3075.	1.1	27
134	Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. <i>Atherosclerosis</i> , 2012, 225, 481-485.	0.4	31
135	Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. <i>European Heart Journal</i> , 2012, 33, 1142-1149.	1.0	171
136	Inhibition of hepatic sulfatase-2 In Vivo: A novel strategy to correct diabetic dyslipidemia. <i>Hepatology</i> , 2012, 55, 1746-1753.	3.6	37
137	Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. <i>Clinical Genetics</i> , 2012, 81, 24-28.	1.0	14
138	Cholesterol Acyltransferase Gene Mutations Have Accelerated Atherogenesis as Assessed by Carotid 3.0-T Magnetic Resonance Imaging. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2481-2487.	1.2	58
139	Physical activity, metabolic syndrome, and coronary risk: the EPICâ€œNorfolk prospective population study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 209-217.	3.1	46
140	Dalcetrapib: turning the tide for CETP inhibition?. <i>Lancet, The</i> , 2011, 378, 1529-1530.	6.3	1
141	Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. <i>Diabetologia</i> , 2010, 53, 2646-2655.	2.9	302
142	Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size. <i>Clinical Chemistry</i> , 2010, 56, 789-798.	1.5	36
143	Lipid Measures and Cardiovascular Disease Prediction. <i>Disease Markers</i> , 2009, 26, 209-216.	0.6	11
144	Safety and Tolerability of Dalcetrapibâ€œConflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Colu. <i>American Journal of Cardiology</i> , 2009, 104, 82-91.	0.7	134

#	ARTICLE	IF	CITATIONS
145	The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors. <i>American Journal of Cardiology</i> , 2009, 104, 32E-38E.	0.7	59
146	Biologic Effects of Simvastatin in Patients with Aneurysmal Subarachnoid Hemorrhage: A Double-Blind, Placebo-Controlled Randomized Trial. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1444-1453.	2.4	118
147	Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. <i>British Journal of Pharmacology</i> , 2009, 158, 1763-1770.	2.7	48
148	Comparison of In Vivo Carotid 3.0-T Magnetic Resonance to B-Mode Ultrasound Imaging and Histology in a Porcine Model. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 744-750.	2.3	8
149	In vivo glycocalyx degradation induces proteinuria and insulin resistance without affecting atherogenesis in apoE knockout mice on a Western-type diet. <i>FASEB Journal</i> , 2009, 23, 950.5.	0.2	0
150	Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. <i>Diabetologia</i> , 2008, 51, 1081-1084.	2.9	62
151	Microthrombosis after Aneurysmal Subarachnoid Hemorrhage: An Additional Explanation for Delayed Cerebral Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1761-1770.	2.4	289
152	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2008, 358, 1431-1443.	13.9	1,180
153	Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. <i>Journal of Applied Physiology</i> , 2008, 104, 845-852.	1.2	170
154	Sulfated glycosaminoglycans restore glycocalyx barrier properties of cultured endothelial cells in hyperglycemia. <i>FASEB Journal</i> , 2008, 22, 83-83.	0.2	6
155	Role of the Apolipoprotein B/Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case-Control Analysis in EPIC-Norfolk. <i>Annals of Internal Medicine</i> , 2007, 146, 640.	2.0	140
156	Antisense Apolipoprotein B-100 As Novel Treatment For Hypercholesterolemia: Focus On Isis 301012. <i>Future Lipidology</i> , 2007, 2, 387-393.	0.5	6
157	High-Density Lipoprotein Attenuates Inflammation and Coagulation Response on Endotoxin Challenge in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1153-1158.	1.1	102
158	Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. <i>Diabetologia</i> , 2007, 50, 1288-1293.	2.9	80
159	Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2007, 12, 1127-1132.	0.6	64
160	Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?. <i>Cardiovascular Research</i> , 2006, 69, 341-347.	1.8	45
161	Lipoprotein Lipase S447X. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1236-1245.	1.1	140
162	Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo. <i>Diabetes</i> , 2006, 55, 480-486.	0.3	469

#	ARTICLE	IF	CITATIONS
163	Endothelial Glycocalyx Damage Coincides With Microalbuminuria in Type 1 Diabetes. <i>Diabetes</i> , 2006, 55, 1127-1132.	0.3	361
164	Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans. <i>Circulation Research</i> , 2005, 96, 714-716.	2.0	208
165	Letter Regarding Article by Luo et al, "Adenovirus-Mediated Expression of $\beta_2$ -Adrenergic Receptor Kinase C-Terminus Reduces Intimal Hyperplasia and Luminal Stenosis of Arteriovenous Polytetrafluoroethylene Grafts in Pigs"; <i>Circulation</i> , 2005, 112, e153; author reply e153.	1.6	1
166	Statins and LDL cholesterol lowering: an overview. <i>Current Medical Research and Opinion</i> , 2005, 21, S9-S16.	0.9	45
167	Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. <i>Journal of the American College of Cardiology</i> , 2005, 45, 185-197.	1.2	402
168	A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1429-1435.	1.2	124
169	Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein. <i>Circulation</i> , 2003, 107, 2944-2948.	1.6	283
170	Measurement of subclinical atherosclerosis: beyond risk factor assessment. <i>Current Opinion in Lipidology</i> , 2002, 13, 595-603.	1.2	37
171	Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. <i>European Journal of Clinical Investigation</i> , 2002, 32, 9-16.	1.7	129
172	Folic Acid Reverts Dysfunction of Endothelial Nitric Oxide Synthase. <i>Circulation Research</i> , 2000, 86, 1129-1134.	2.0	265
173	Influence of Folic Acid on Postprandial Endothelial Dysfunction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 185-188.	1.1	150
174	Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction?. <i>Atherosclerosis</i> , 1998, 137, S51-S60.	0.4	51
175	Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?. <i>Cardiovascular Research</i> , 1998, 39, 543-549.	1.8	9